Gastrointestinal stromal tumor medical therapy: Difference between revisions
Jump to navigation
Jump to search
| (26 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The | The mainstay of treatment for gastrointestinal stromal tumor (GIST) is surgical [[resection]]. [[Medicine|Medical]] [[therapy]] with [[Protein kinase inhibitor|tyrosine kinase inhibitors]] are indicated in [[Patient|patients]] with unresectable [[Lesion|lesions]], to decrease [[tumor]] size prior to [[surgery]] and for prevention of recurrent [[disease]]. [[Imatinib]] 400 mg to 800 mg PO q24h is the [[drug]] of choice for [[Patient|patients]] with aforementioned conditions. [[Patient|Patients]] resistant to [[imatinib]] are treated with [[sunitinib]] 50 mg PO q24h. [[Medicine|Medical]] [[therapy]] such as fluid [[resuscitation]], [[Antibiotic|antibiotics]] cover, [[deep venous thrombosis]] prophylaxis should also be given to decrease [[perioperative]] [[morbidity]] associated with [[resection]] of GIST. | ||
==Medical Therapy== | ==Medical Therapy== | ||
*The treatment options for gastrointestinal stromal tumor (GIST) include surgical therapy, [[chemotherapy]] and [[Tyrosine kinase inhibitors|tyrosine kinase inhibitor]] therapy. | * | ||
*[[Laparoscopic surgery|Laparoscopic]] or [[Endoscopic surgery|endoscopic]] surgical resection is the first-line treatment for primary and localized GIST. However, with advanced disease where surgery is not an option (unresectable lesions), patients are treated with [[tyrosine kinase inhibitor]] therapy. | *The treatment options for gastrointestinal stromal tumor (GIST) include surgical [[therapy]], [[chemotherapy]] and [[Tyrosine kinase inhibitors|tyrosine kinase inhibitor]] [[therapy]].<ref name="pmid29760538">{{cite journal |vauthors=Sanchez-Hidalgo JM, Duran-Martinez M, Molero-Payan R, Rufian-Peña S, Arjona-Sanchez A, Casado-Adam A, Cosano-Alvarez A, Briceño-Delgado J |title=Gastrointestinal stromal tumors: A multidisciplinary challenge |journal=World J. Gastroenterol. |volume=24 |issue=18 |pages=1925–1941 |date=May 2018 |pmid=29760538 |pmc=5949708 |doi=10.3748/wjg.v24.i18.1925 |url=}}</ref><ref name="pmid23847717">{{cite journal |vauthors=Rammohan A, Sathyanesan J, Rajendran K, Pitchaimuthu A, Perumal SK, Srinivasan U, Ramasamy R, Palaniappan R, Govindan M |title=A gist of gastrointestinal stromal tumors: A review |journal=World J Gastrointest Oncol |volume=5 |issue=6 |pages=102–12 |date=June 2013 |pmid=23847717 |pmc=3708046 |doi=10.4251/wjgo.v5.i6.102 |url=}}</ref><ref name="pmid30697609">{{cite journal |vauthors=Iwatsuki M, Harada K, Iwagami S, Eto K, Ishimoto T, Baba Y, Yoshida N, Ajani JA, Baba H |title=Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors |journal=Ann Gastroenterol Surg |volume=3 |issue=1 |pages=43–49 |date=January 2019 |pmid=30697609 |pmc=6345649 |doi=10.1002/ags3.12211 |url=}}</ref><ref name="pmid24293969">{{cite journal |vauthors=Sreevathsa MR |title=Caecal gastrointestinal stromal tumor with perforation and obstruction |journal=Indian J Surg Oncol |volume=3 |issue=4 |pages=311–3 |date=December 2012 |pmid=24293969 |pmc=3521553 |doi=10.1007/s13193-012-0185-8 |url=}}</ref><ref name="pmid26405414">{{cite journal |vauthors=Bava EP, Sharma A, Chumber S, Anand RK |title=Gastrointestinal Stromal Tumour in a Patient with Multiple Cutaneous and Uterine Leiomyomatosis- Implications and Anaesthetic Management |journal=Indian J Surg Oncol |volume=6 |issue=2 |pages=106–9 |date=June 2015 |pmid=26405414 |pmc=4577480 |doi=10.1007/s13193-014-0366-8 |url=}}</ref> | ||
*Medical therapy is also given as part of [[Pre op work up|pre]] and post-operative care to reduce the risk of [[morbidity]] associated with surgical [[resection]] of GIST. | *[[Laparoscopic surgery|Laparoscopic]] or [[Endoscopic surgery|endoscopic]] surgical [[resection]] is the first-line treatment for primary and localized GIST. However, with advanced [[disease]] where [[surgery]] is not an option (unresectable lesions), [[Patient|patients]] are treated with [[tyrosine kinase inhibitor]] [[therapy]]. | ||
**Peri-operative [[fluid resuscitation]] and [[Blood transfusion|transfusion]] preferably with ringer lactate or [[normal saline]] may be given along with urinary | *[[Medical]] [[therapy]] is also given as part of [[Pre op work up|pre]] and post-operative care to reduce the risk of [[morbidity]] associated with surgical [[resection]] of GIST. | ||
**[[Diet]] and [[nutrition]]: Specific peri-operative diet and nutrition ([[multivitamin]] and [[mineral supplements]]) may given either through a Ryle's tube or a peripheral/central line. | **Peri-operative [[fluid resuscitation]] and [[Blood transfusion|transfusion]] preferably with ringer lactate or [[normal saline]] may be given along with urinary foley's catheter to monitor fluid intake and output. | ||
**[[Antibiotics]] cover: Patients with signs and symptoms of [[bowel perforation]] or [[infarction]] should be treated with intravenous [[antibiotic]] prophylaxis to prevent surgical wound infection and [[sepsis]]. | **[[Diet]] and [[nutrition]]: | ||
**Pain and [[deep venous thrombosis]] (DVT) prophylaxis: Appropriate pain control ([[NSAID]] or [[morphine]]) and prophylaxis for [[Deep vein thrombosis|DVT]] ([[heparin]]) may be given as a precautionary therapy in patients complaining of [[pain]] or [[Dyspnea|breathlessness]]. | ***Specific peri-operative diet and nutrition ([[multivitamin]] and [[mineral supplements]]) may given either through a Ryle's tube or a peripheral/central line. | ||
**[[Antibiotics]] cover: | |||
***[[Patient|Patients]] with signs and [[Symptom|symptoms]] of [[bowel perforation]] or [[infarction]] should be treated with intravenous [[antibiotic]] prophylaxis to prevent surgical wound [[infection]] and [[sepsis]]. | |||
**[[Pain]] and [[deep venous thrombosis]] ([[Deep vein thrombosis|DVT]]) [[prophylaxis]]: | |||
***Appropriate [[pain]] control ([[NSAID]] or [[morphine]]) and [[prophylaxis]] for [[Deep vein thrombosis|DVT]] ([[heparin]]) may be given as a precautionary [[therapy]] in [[Patient|patients]] complaining of [[pain]] or [[Dyspnea|breathlessness]]. | |||
==Chemotherapy== | ==Chemotherapy== | ||
*The advent of [[molecular genetics]] has drastically changed the management and outlook of patients with GIST. | *The advent of [[molecular genetics]] has drastically changed the management and outlook of [[Patient|patients]] with GIST.<ref name="pmid20436835">{{cite journal |vauthors=Peralta EA |title=Rare anorectal neoplasms: gastrointestinal stromal tumor, carcinoid, and lymphoma |journal=Clin Colon Rectal Surg |volume=22 |issue=2 |pages=107–14 |date=May 2009 |pmid=20436835 |pmc=2780247 |doi=10.1055/s-0029-1223842 |url=}}</ref> | ||
*The [[tyrosine kinase inhibitors]] are the drug of choice for medical management of patients with GIST.<ref name="pmid12181401">{{cite journal |vauthors=Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H |title=Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors |journal=N. Engl. J. Med. |volume=347 |issue=7 |pages=472–80 |year=2002 |pmid=12181401 |doi=10.1056/NEJMoa020461 |url=}}</ref> | *The [[tyrosine kinase inhibitors]] are the [[drug]] of choice for [[medical]] management of [[Patient|patients]] with GIST.<ref name="pmid12181401">{{cite journal |vauthors=Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H |title=Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors |journal=N. Engl. J. Med. |volume=347 |issue=7 |pages=472–80 |year=2002 |pmid=12181401 |doi=10.1056/NEJMoa020461 |url=}}</ref> | ||
**Prior to the use of tyrosine kinase inhibitors, conventional chemotherapy were not effective in treating patients with GIST.<ref name="pmid19303137">{{cite journal |vauthors=Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K |title=Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial |journal=Lancet |volume=373 |issue=9669 |pages=1097–104 |year=2009 |pmid=19303137 |pmc=2915459 |doi=10.1016/S0140-6736(09)60500-6 |url=}}</ref> | **Prior to the use of [[Protein kinase inhibitor|tyrosine kinase inhibitors]], conventional [[chemotherapy]] were not effective in treating [[Patient|patients]] with GIST.<ref name="pmid19303137">{{cite journal |vauthors=Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K |title=Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial |journal=Lancet |volume=373 |issue=9669 |pages=1097–104 |year=2009 |pmid=19303137 |pmc=2915459 |doi=10.1016/S0140-6736(09)60500-6 |url=}}</ref> | ||
**Cells with MRP1 (multidrug resistance protein-1) and MDR-1 (multidrug resistance-1) gene produce [[P-glycoprotein]] that led to increased expression of cellular [[efflux pumps]] and prevented conventional [[chemotherapy]] agents to attain appropriate therapeutic levels. | **[[Cell (biology)|Cells]] with MRP1 ([[multidrug resistance]] [[protein]]-1) and [[MDR]]-1 (multidrug resistance-1) gene produce [[P-glycoprotein]] that led to increased expression of cellular [[efflux pumps]] and prevented conventional [[chemotherapy]] agents to attain appropriate [[therapeutic]] levels. | ||
===Tyrosine Kinase Inhibitor Therapy=== | ===Tyrosine Kinase Inhibitor Therapy=== | ||
*[[Imatinib]] is a selective [[tyrosine kinase inhibitor]] (TKI) effective against KIT, PDGFRA, and [[chronic myelogenous leukemia]] specific BCR-ABL protein.<ref name="pmid22453568">{{cite journal |vauthors=Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P |title=One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial |journal=JAMA |volume=307 |issue=12 |pages=1265–72 |year=2012 |pmid=22453568 |doi=10.1001/jama.2012.347 |url=}}</ref><ref name="pmid20457867">{{cite journal |vauthors=Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD |title=NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors |journal=J Natl Compr Canc Netw |volume=8 Suppl 2 |issue= |pages=S1–41; quiz S42–4 |year=2010 |pmid=20457867 |pmc=4103754 |doi= |url=}}</ref><ref name="pmid17046465">{{cite journal |vauthors=Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG |title=Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial |journal=Lancet |volume=368 |issue=9544 |pages=1329–38 |year=2006 |pmid=17046465 |doi=10.1016/S0140-6736(06)69446-4 |url=}}</ref> | *[[Imatinib]] is a selective [[tyrosine kinase inhibitor]] (TKI) effective against KIT, PDGFRA, and [[chronic myelogenous leukemia]] specific [[BCR/ABL|BCR-ABL]] [[protein]].<ref name="pmid22453568">{{cite journal |vauthors=Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P |title=One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial |journal=JAMA |volume=307 |issue=12 |pages=1265–72 |year=2012 |pmid=22453568 |doi=10.1001/jama.2012.347 |url=}}</ref><ref name="pmid20457867">{{cite journal |vauthors=Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD |title=NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors |journal=J Natl Compr Canc Netw |volume=8 Suppl 2 |issue= |pages=S1–41; quiz S42–4 |year=2010 |pmid=20457867 |pmc=4103754 |doi= |url=}}</ref><ref name="pmid17046465">{{cite journal |vauthors=Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG |title=Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial |journal=Lancet |volume=368 |issue=9544 |pages=1329–38 |year=2006 |pmid=17046465 |doi=10.1016/S0140-6736(06)69446-4 |url=}}</ref><ref name="pmid21814597">{{cite journal |vauthors=Jung SH, Suh KS, Kang DY, Kang DW, Kim YB, Kim ES |title=Expression of DOG1, PDGFRA, and p16 in Gastrointestinal Stromal Tumors |journal=Gut Liver |volume=5 |issue=2 |pages=171–80 |date=June 2011 |pmid=21814597 |pmc=3140662 |doi=10.5009/gnl.2011.5.2.171 |url=}}</ref><ref name="pmid238477172">{{cite journal |vauthors=Rammohan A, Sathyanesan J, Rajendran K, Pitchaimuthu A, Perumal SK, Srinivasan U, Ramasamy R, Palaniappan R, Govindan M |title=A gist of gastrointestinal stromal tumors: A review |journal=World J Gastrointest Oncol |volume=5 |issue=6 |pages=102–12 |date=June 2013 |pmid=23847717 |pmc=3708046 |doi=10.4251/wjgo.v5.i6.102 |url=}}</ref><ref name="IshikawaKanda2018">{{cite journal|last1=Ishikawa|first1=Takashi|last2=Kanda|first2=Tatsuo|last3=Kameyama|first3=Hitoshi|last4=Wakai|first4=Toshifumi|title=Neoadjuvant therapy for gastrointestinal stromal tumor|journal=Translational Gastroenterology and Hepatology|volume=3|year=2018|pages=3–3|issn=24151289|doi=10.21037/tgh.2018.01.01}}</ref> | ||
*In addition, around 95 % patients with GIST stain positive for mutated CD117 (KIT) and 5-10% for mutated PDGFRA. These patients may be treated with agents acting against CD117 and PDGFRA ([[tyrosine kinase inhibitor]] therapy). | *In addition, around 95 % [[Patient|patients]] with GIST [[stain]] positive for [[mutated]] [[CD117]] (KIT) and 5-10% for [[Mutation|mutated]] PDGFRA. These [[Patient|patients]] may be treated with agents acting against CD117 and PDGFRA ([[tyrosine kinase inhibitor]] [[therapy]]). | ||
*The [[tyrosine kinase inhibitor]] (TKI) [[imatinib mesylate]] is used as the first-line treatment for unresectable lesions (such as large primary GIST, metastatic or recurrent GIST). | *The [[tyrosine kinase inhibitor]] (TKI) [[imatinib mesylate]] is used as the first-line treatment for unresectable [[Lesion|lesions]] (such as large primary GIST, [[Metastasis|metastatic]] or recurrent GIST). | ||
*Surgery is associated with greater [[morbidity]] and mortality in patients with unresectable lesions. | *[[Surgery]] is associated with greater [[morbidity]] and [[mortality]] in [[Patient|patients]] with unresectable [[Lesion|lesions]]. | ||
*The benefit of TKI is largely evident from the fact that median survival rates have gone from less than 2 years to more than 5 years with the use of [[imatinib]] therapy. | *The benefit of TKI is largely evident from the fact that median [[Survival rate|survival rates]] have gone from less than 2 years to more than 5 years with the use of [[imatinib]] [[therapy]]. | ||
*Recent studies also recommend the use of [[imatinib]] to decrease the recurrence rate in patients undergoing [[resection]] for primary GIST. | *Recent studies also recommend the use of [[imatinib]] to decrease the recurrence rate in [[Patient|patients]] undergoing [[resection]] for primary GIST. | ||
*[[Imatinib]] is also used to shrink tumor prior to surgery. | *[[Imatinib]] is also used to shrink [[tumor]] prior to [[surgery]]. | ||
** 1.1 '''Tyrosine kinase inhibitor (TKI) ''' | ** 1.1 '''Tyrosine kinase inhibitor (TKI) ''' | ||
** 1.1.1 '''Unresectable lesions''' such as large primary GIST, metastatic or recurrent GIST. | ** 1.1.1 '''Unresectable lesions''' such as large primary GIST, [[Metastasis|metastatic]] or recurrent GIST. | ||
*** Preferred regimen (1): [[Imatinib]] 400 mg to 800 mg PO q24h | *** Preferred regimen (1): [[Imatinib]] 400 mg to 800 mg PO q24h | ||
**:'''Note (1):'''For unresectable lesions the treatment is usually life long. | **:'''Note (1):'''For unresectable [[Lesion|lesions]] the treatment is usually life long. | ||
**:'''Note (2):'''Use of 800 mg daily dose has been observed with significant improvement in patients with KIT exon 9 mutation. | **:'''Note (2):'''Use of 800 mg daily dose has been observed with significant improvement in [[Patient|patients]] with KIT [[exon]] 9 [[mutation]]. | ||
**:'''Note (3):'''Patients resistant to 400 mg imatinib should have their dose increased to 800 mg PO q24h. | **:'''Note (3):'''[[Patient|Patients]] resistant to 400 mg [[imatinib]] should have their dose increased to 800 mg PO q24h. | ||
*** Alternative regimen (1): [[Sunitinib]] 50 mg PO q24h | *** Alternative regimen (1): [[Sunitinib]] 50 mg PO q24h | ||
**:'''Note (1):'''[[Sunitinib]] is given in 6 weeks cycle (with intake for 4 weeks and abstinence for 2 weeks). | **:'''Note (1):'''[[Sunitinib]] is given in 6 weeks cycle (with intake for 4 weeks and abstinence for 2 weeks). | ||
| Line 42: | Line 46: | ||
===Drug side effects=== | ===Drug side effects=== | ||
Common side effects of imatinib therapy include:<ref name="pmid10910906">{{cite journal |vauthors=Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ |title=Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor |journal=Blood |volume=96 |issue=3 |pages=925–32 |year=2000 |pmid=10910906 |doi= |url=}}</ref> | Common side effects of [[imatinib]] [[therapy]] include:<ref name="pmid10910906">{{cite journal |vauthors=Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ |title=Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor |journal=Blood |volume=96 |issue=3 |pages=925–32 |year=2000 |pmid=10910906 |doi= |url=}}</ref> | ||
*Fluid retention | *[[Fluid]] [[retention]] | ||
*[[Diarrhea]] | *[[Diarrhea]] | ||
*[[Nausea]] | *[[Nausea]] | ||
| Line 52: | Line 56: | ||
*Mild (macrocytic) [[anemia]] | *Mild (macrocytic) [[anemia]] | ||
Common side effects associated with [[sunitinib]] therapy include the following: | Common side effects associated with [[sunitinib]] [[therapy]] include the following: | ||
*[[Fatigue (physical)|Fatigue]] | *[[Fatigue (physical)|Fatigue]] | ||
*[[Nausea and vomiting]] | *[[Nausea and vomiting]] | ||
| Line 61: | Line 65: | ||
*[[Mucositis]] | *[[Mucositis]] | ||
*[[Anorexia]] | *[[Anorexia]] | ||
*Skin or hair discoloration | *[[Skin]] or [[hair]] discoloration | ||
*[[Hypothyroidism]] | *[[Hypothyroidism]] | ||
Latest revision as of 03:15, 4 March 2019
|
Gastrointestinal stromal tumor Microchapters |
|
Differentiating Gastrointestinal stromal tumor from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastrointestinal stromal tumor medical therapy On the Web |
|
American Roentgen Ray Society Images of Gastrointestinal stromal tumor medical therapy |
|
Directions to Hospitals Treating Gastrointestinal stromal tumor |
|
Risk calculators and risk factors for Gastrointestinal stromal tumor medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]Parminder Dhingra, M.D. [3]
Overview
The mainstay of treatment for gastrointestinal stromal tumor (GIST) is surgical resection. Medical therapy with tyrosine kinase inhibitors are indicated in patients with unresectable lesions, to decrease tumor size prior to surgery and for prevention of recurrent disease. Imatinib 400 mg to 800 mg PO q24h is the drug of choice for patients with aforementioned conditions. Patients resistant to imatinib are treated with sunitinib 50 mg PO q24h. Medical therapy such as fluid resuscitation, antibiotics cover, deep venous thrombosis prophylaxis should also be given to decrease perioperative morbidity associated with resection of GIST.
Medical Therapy
- The treatment options for gastrointestinal stromal tumor (GIST) include surgical therapy, chemotherapy and tyrosine kinase inhibitor therapy.[1][2][3][4][5]
- Laparoscopic or endoscopic surgical resection is the first-line treatment for primary and localized GIST. However, with advanced disease where surgery is not an option (unresectable lesions), patients are treated with tyrosine kinase inhibitor therapy.
- Medical therapy is also given as part of pre and post-operative care to reduce the risk of morbidity associated with surgical resection of GIST.
- Peri-operative fluid resuscitation and transfusion preferably with ringer lactate or normal saline may be given along with urinary foley's catheter to monitor fluid intake and output.
- Diet and nutrition:
- Specific peri-operative diet and nutrition (multivitamin and mineral supplements) may given either through a Ryle's tube or a peripheral/central line.
- Antibiotics cover:
- Patients with signs and symptoms of bowel perforation or infarction should be treated with intravenous antibiotic prophylaxis to prevent surgical wound infection and sepsis.
- Pain and deep venous thrombosis (DVT) prophylaxis:
- Appropriate pain control (NSAID or morphine) and prophylaxis for DVT (heparin) may be given as a precautionary therapy in patients complaining of pain or breathlessness.
Chemotherapy
- The advent of molecular genetics has drastically changed the management and outlook of patients with GIST.[6]
- The tyrosine kinase inhibitors are the drug of choice for medical management of patients with GIST.[7]
- Prior to the use of tyrosine kinase inhibitors, conventional chemotherapy were not effective in treating patients with GIST.[8]
- Cells with MRP1 (multidrug resistance protein-1) and MDR-1 (multidrug resistance-1) gene produce P-glycoprotein that led to increased expression of cellular efflux pumps and prevented conventional chemotherapy agents to attain appropriate therapeutic levels.
Tyrosine Kinase Inhibitor Therapy
- Imatinib is a selective tyrosine kinase inhibitor (TKI) effective against KIT, PDGFRA, and chronic myelogenous leukemia specific BCR-ABL protein.[9][10][11][12][13][14]
- In addition, around 95 % patients with GIST stain positive for mutated CD117 (KIT) and 5-10% for mutated PDGFRA. These patients may be treated with agents acting against CD117 and PDGFRA (tyrosine kinase inhibitor therapy).
- The tyrosine kinase inhibitor (TKI) imatinib mesylate is used as the first-line treatment for unresectable lesions (such as large primary GIST, metastatic or recurrent GIST).
- Surgery is associated with greater morbidity and mortality in patients with unresectable lesions.
- The benefit of TKI is largely evident from the fact that median survival rates have gone from less than 2 years to more than 5 years with the use of imatinib therapy.
- Recent studies also recommend the use of imatinib to decrease the recurrence rate in patients undergoing resection for primary GIST.
- Imatinib is also used to shrink tumor prior to surgery.
- 1.1 Tyrosine kinase inhibitor (TKI)
- 1.1.1 Unresectable lesions such as large primary GIST, metastatic or recurrent GIST.
- Preferred regimen (1): Imatinib 400 mg to 800 mg PO q24h
- Note (1):For unresectable lesions the treatment is usually life long.
- Note (2):Use of 800 mg daily dose has been observed with significant improvement in patients with KIT exon 9 mutation.
- Note (3):Patients resistant to 400 mg imatinib should have their dose increased to 800 mg PO q24h.
- Alternative regimen (1): Sunitinib 50 mg PO q24h
- Note (1):Sunitinib is given in 6 weeks cycle (with intake for 4 weeks and abstinence for 2 weeks).
- Note (2):Sunitinib has both antiangiogenic and anti-tumor effects.
- 1.1.2 Adjuvant therapy after resection
- Preferred regimen (1): Imatinib 400 mg PO q24h
- Note (1):For Adjuvant therapy after resection the recommended duration of treatment is 3 years.
Drug side effects
Common side effects of imatinib therapy include:[15]
- Fluid retention
- Diarrhea
- Nausea
- Fatigue
- Muscle cramps
- Abdominal pain
- Rash
- Mild (macrocytic) anemia
Common side effects associated with sunitinib therapy include the following:
- Fatigue
- Nausea and vomiting
- Anemia
- Neutropenia
- Diarrhea
- Abdominal pain
- Mucositis
- Anorexia
- Skin or hair discoloration
- Hypothyroidism
References
- ↑ Sanchez-Hidalgo JM, Duran-Martinez M, Molero-Payan R, Rufian-Peña S, Arjona-Sanchez A, Casado-Adam A, Cosano-Alvarez A, Briceño-Delgado J (May 2018). "Gastrointestinal stromal tumors: A multidisciplinary challenge". World J. Gastroenterol. 24 (18): 1925–1941. doi:10.3748/wjg.v24.i18.1925. PMC 5949708. PMID 29760538.
- ↑ Rammohan A, Sathyanesan J, Rajendran K, Pitchaimuthu A, Perumal SK, Srinivasan U, Ramasamy R, Palaniappan R, Govindan M (June 2013). "A gist of gastrointestinal stromal tumors: A review". World J Gastrointest Oncol. 5 (6): 102–12. doi:10.4251/wjgo.v5.i6.102. PMC 3708046. PMID 23847717.
- ↑ Iwatsuki M, Harada K, Iwagami S, Eto K, Ishimoto T, Baba Y, Yoshida N, Ajani JA, Baba H (January 2019). "Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors". Ann Gastroenterol Surg. 3 (1): 43–49. doi:10.1002/ags3.12211. PMC 6345649. PMID 30697609.
- ↑ Sreevathsa MR (December 2012). "Caecal gastrointestinal stromal tumor with perforation and obstruction". Indian J Surg Oncol. 3 (4): 311–3. doi:10.1007/s13193-012-0185-8. PMC 3521553. PMID 24293969.
- ↑ Bava EP, Sharma A, Chumber S, Anand RK (June 2015). "Gastrointestinal Stromal Tumour in a Patient with Multiple Cutaneous and Uterine Leiomyomatosis- Implications and Anaesthetic Management". Indian J Surg Oncol. 6 (2): 106–9. doi:10.1007/s13193-014-0366-8. PMC 4577480. PMID 26405414.
- ↑ Peralta EA (May 2009). "Rare anorectal neoplasms: gastrointestinal stromal tumor, carcinoid, and lymphoma". Clin Colon Rectal Surg. 22 (2): 107–14. doi:10.1055/s-0029-1223842. PMC 2780247. PMID 20436835.
- ↑ Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002). "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors". N. Engl. J. Med. 347 (7): 472–80. doi:10.1056/NEJMoa020461. PMID 12181401.
- ↑ Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K (2009). "Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial". Lancet. 373 (9669): 1097–104. doi:10.1016/S0140-6736(09)60500-6. PMC 2915459. PMID 19303137.
- ↑ Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P (2012). "One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial". JAMA. 307 (12): 1265–72. doi:10.1001/jama.2012.347. PMID 22453568.
- ↑ Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD (2010). "NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors". J Natl Compr Canc Netw. 8 Suppl 2: S1–41, quiz S42–4. PMC 4103754. PMID 20457867.
- ↑ Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006). "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial". Lancet. 368 (9544): 1329–38. doi:10.1016/S0140-6736(06)69446-4. PMID 17046465.
- ↑ Jung SH, Suh KS, Kang DY, Kang DW, Kim YB, Kim ES (June 2011). "Expression of DOG1, PDGFRA, and p16 in Gastrointestinal Stromal Tumors". Gut Liver. 5 (2): 171–80. doi:10.5009/gnl.2011.5.2.171. PMC 3140662. PMID 21814597.
- ↑ Rammohan A, Sathyanesan J, Rajendran K, Pitchaimuthu A, Perumal SK, Srinivasan U, Ramasamy R, Palaniappan R, Govindan M (June 2013). "A gist of gastrointestinal stromal tumors: A review". World J Gastrointest Oncol. 5 (6): 102–12. doi:10.4251/wjgo.v5.i6.102. PMC 3708046. PMID 23847717.
- ↑ Ishikawa, Takashi; Kanda, Tatsuo; Kameyama, Hitoshi; Wakai, Toshifumi (2018). "Neoadjuvant therapy for gastrointestinal stromal tumor". Translational Gastroenterology and Hepatology. 3: 3–3. doi:10.21037/tgh.2018.01.01. ISSN 2415-1289.
- ↑ Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ (2000). "Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor". Blood. 96 (3): 925–32. PMID 10910906.